ARMATA PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $508.00K.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $704.00K.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $0.00.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $658.00K, a 406.15% increase from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $130.00K, a 2500.00% increase from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $5.00K, a 96.00% decline from fiscal 2022.
- ARMATA PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $125.00K, a 61.18% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $508.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $704.00K 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $658.00K 10-K · filed 2026-03-25 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $130.00K 10-K · filed 2026-03-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $130.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $88.00K 10-Q · filed 2025-08-12 | $135.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $42.00K 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $5.00K 10-K · filed 2025-03-21 |
| 2023-09-30 | $5.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $71.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $125.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $54.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $71.00K 10-Q · filed 2023-08-14 | |
| 2021-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $322.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $86.00K 10-Q · filed 2022-11-09 | $240.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $241.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $154.00K 10-Q · filed 2022-05-12 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $87.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $87.00K 10-Q · filed 2021-11-10 | |
| 2013-12-31 | $13.00K 10-Q/A · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |